Targeting Obesity: Win Some, Lose Some

Targeting obesity with new treatments presents remarkable challenges. For evidence of this harsh reality, look at the sharply contrasting news this week for two potential new drugs: beloranib and setmelanotide. All work on beloranib was canceled by its developer, Zafgen. Almost simultaneously, Rhythm Pharmaceuticals published breakthrough results in the New England Journal of Medicine (NEJM) with setmelanotide for a tiny group of patients.

Beloranib, which inhibits an enzyme called METAP2, had shown considerable promise for treating two rare and sever forms of obesity: Prader-Willi syndrome and obesity caused by injury to the brain’s hypothalamus. The first big setback for beloranib came in October last year with a patient death in clinical trials due to a blood clot. A second death brought a halt to all clinical trials in December.

This week, Zafgen called it quits for beloranib, because the company could not work out a strategy for addressing the safety concerns. Instead, Zafgen will shift its resources to a newer, potentially safer drug with the same mechanisim of action. The company’s labors to bring a drug for severe obesity to market earn our respect for persistence and focus.

A happier story emerged for Rhythm Pharmaceuticals this week. NEJM published impressive results for its new activator of the melanocortin-4 receptor setmelanotide. Two patients with a rare condition, Proopiomelanocortin (POMC) Deficiency, experienced striking responses to treatment with the new drug. POMC deficiency causes extreme hunger and severe obesity at an early age. It is virtually impossible to treat with much success.

Setmelanotide produced a sustained reduction in hunger and significant weight loss in both patients. The study reports data for 12 weeks with one of the patients and 42 weeks with the other.

As the roller coaster ride for Zafgen illustrates, these exciting results with setmelanotide represent nothing more than a good start. But they do point to the promise of serously targeting obesity in the many different forms it takes.

Just as different forms and stages of cancer require different treatments, we are learning that different forms of obesity can be successfully treated with targeted therapies.

Click here for the study of setmelanotide and here for more perspective from Fierce Biotech. Click here for more from Seeking Alpha on Zafgen and its challenges.

Blocked Off, photograph © Darwin Bell / flickr

Subscribe by email to follow the accumulating evidence and observations that shape our view of health, obesity, and policy.


July 22, 2016

2 Responses to “Targeting Obesity: Win Some, Lose Some”

  1. July 22, 2016 at 9:32 am, Allen Browne said:

    For many, childhood is when obesity starts. Obesity may be easier to treat earlier. Obesity does have many different forms and research in identifying these forms is necessary. Treatment specific to each form will be more successful. We need to study each type of treatment to understand it. Then we can match the type of treatment to the form of disease. Much to do and little being done. But today is the first day of the rest of our lives.

  2. July 22, 2016 at 11:43 am, Stephen Phillips said:

    Bariatric scientists have begun to unravel the myriad of chemical and neuronal messengers that “start and stop a meal” Identifying these messenger will inevitably lead to pharmaceuticals that will successfully provide treatment and prevention of obesities.

    A shining example of this emerging science is setmelanotide, a chemical agent, that in a pilot study of two patients, has been used to successfully treat a rare genetic form of obesity, which has effectively been untreatable.

    Kudos to the pioneering work of Rhythm Pharmaceuticals, the developers of this agent.

    “Hope is my nursemaid”…. Socrates

    Stephen Phillips
    American Association of Bariatric Science